Why Aren't MAOIs Used More Often?

While I have spent most of my last 45 years in psychiatry working in an academic setting and doing clinical research, I have always had an active practice focused on major affective disorders, especially treatment-resistant or treatment-refractory cases. It is my impression that monoamine oxidase inhibitors (MAOIs) are currently underutilized in the clinical practice of psychiatry. Very few of the treatment-resistant patients that I see have received a serious trial of MAOI therapy.

J Clin Psychiatry 2009;70(1):139-140